StockNews.com downgraded shares of Electromed (NYSE:ELMD – Free Report) from a strong-buy rating to a buy rating in a report released on Thursday morning.
Electromed Trading Up 2.7 %
Shares of NYSE:ELMD opened at $31.12 on Thursday. Electromed has a 12 month low of $9.90 and a 12 month high of $31.88. The company has a market capitalization of $263.28 million, a price-to-earnings ratio of 39.14 and a beta of 0.29. The firm’s 50-day moving average is $28.40 and its 200 day moving average is $21.41.
Electromed (NYSE:ELMD – Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported $0.16 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.13. The firm had revenue of $14.67 million for the quarter. Electromed had a return on equity of 15.32% and a net margin of 11.34%.
Insider Buying and Selling
Hedge Funds Weigh In On Electromed
Hedge funds and other institutional investors have recently made changes to their positions in the company. State Street Corp grew its holdings in Electromed by 14.5% during the 3rd quarter. State Street Corp now owns 22,066 shares of the company’s stock worth $474,000 after acquiring an additional 2,800 shares in the last quarter. Gabelli Funds LLC boosted its stake in shares of Electromed by 7.8% during the second quarter. Gabelli Funds LLC now owns 38,675 shares of the company’s stock valued at $581,000 after purchasing an additional 2,808 shares in the last quarter. Pekin Hardy Strauss Inc. increased its holdings in Electromed by 9.9% during the third quarter. Pekin Hardy Strauss Inc. now owns 38,185 shares of the company’s stock valued at $820,000 after buying an additional 3,435 shares during the period. Renaissance Technologies LLC raised its stake in Electromed by 4.8% in the second quarter. Renaissance Technologies LLC now owns 103,004 shares of the company’s stock worth $1,548,000 after buying an additional 4,736 shares in the last quarter. Finally, Barclays PLC purchased a new stake in Electromed during the third quarter worth $215,000. Institutional investors own 40.82% of the company’s stock.
Electromed Company Profile
Electromed, Inc develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions.
Read More
- Five stocks we like better than Electromed
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- MercadoLibre: Latin America’s Digital Titan Just Got Cheaper
- Using the MarketBeat Dividend Yield Calculator
- Breaking Down Pegasystems, A Wedbush Top AI Pick for 2025
- Stock Dividend Cuts Happen Are You Ready?
- Shutterstock and Getty: A $3.7 Billion Visual Content Giant
Receive News & Ratings for Electromed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Electromed and related companies with MarketBeat.com's FREE daily email newsletter.